H.Con.Res. 42 · 117th Congress
Expressing the sense of Congress that governmental entities should use a portion of the proceeds from…
Full title
Expressing the sense of Congress that governmental entities should use a portion of the proceeds from litigation against opioid manufacturers and distributors to increase participation in drug take back programs and for the safe disposal of collected, unused medicines.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
McKinleySponsor17 cosponsors · 7 D, 10 R
D
Trone
WT
R
Timmons
MD
D
Dean
MM
R
Miller-Meeks
JH
R
Hill
RK
D
Krishnamoorthi
TR
D
Ryan
RD
R
Davis
JW
R
Wilson
MD
D
DeSaulnier
CP
D
Pappas
AC
D
Craig
JD
R
Duncan
BF
R
Fitzpatrick
AG
R
Garbarino
HR
R
Rogers
NM
R
Mace1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This concurrent resolution expresses the sense of Congress that government entities should consider using a portion of proceeds from litigation against opioid manufacturers and distributors for drug take-back programs.
What it does: CRS summary · Introduced in House · Jul 21, 2021
This concurrent resolution expresses the sense of Congress that government entities should consider using a portion of proceeds from litigation against opioid manufacturers and distributors for drug take-back programs.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Expressing the sense of Congress that governmental entities should use a portion of the proceeds from litigation against opioid manufacturers and distributors to increase participation in drug take back programs and for the safe disposal of collected, unused medicines.
Latest action (Jul 22, 2021): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jul 21, 2021
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.